The DHF, DMR, DHR, EU MDR Technical Documentation Similarities, Differences and The Future (April 28, 2023)
April 06, 2023 09:38 ET
|
Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "The DHF, DMR, DHR, EU MDR Technical Documentation Similarities, Differences and The Future" training has been added to ResearchAndMarkets.com's...
Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course (April 19-20, 2023)
March 31, 2023 07:43 ET
|
Research and Markets
Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course" training has been added to ...
cGMP Regulatory Inspections Webinar: Key Areas of How ICH Q7 was Established - Through the Eyes of FDA, EMA and PMDA
March 28, 2023 10:38 ET
|
Research and Markets
Dublin, March 28, 2023 (GLOBE NEWSWIRE) -- The "cGMP Regulatory Inspections - Through the Eyes of FDA, EMA and PMDA Webinar" webinar has been added to ResearchAndMarkets.com's offering. This...
2 Day Seminar: Health Canada/USP/EP Raw Material Requirements in a cGMP Environment Issues and Solutions (Philadelphia, PA, United States - March 16-17, 2023)
March 17, 2023 05:28 ET
|
Research and Markets
Dublin, March 17, 2023 (GLOBE NEWSWIRE) -- The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions" training has been added to ResearchAndMarkets.com's...
PharmAla Biotech Completes Annual General Meeting
March 01, 2023 08:00 ET
|
PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
March 01, 2023 07:30 ET
|
Optimi Health Corp.
Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
February 28, 2023 02:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
February 14, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that, in the wake of a landmark decision by the...
Dipharma completes second phase of CGMP expansion at its Kalamazoo site
February 10, 2023 10:29 ET
|
Dipharma Francis S.r.l
MILAN, Italy, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a global CDMO and leading manufacturer of Active Pharmaceutical Ingredients and advanced Intermediates, announced...
One Month Remains to Register for the cGMP Regulatory Inspections Course - Through the Eyes of FDA, EMA and PMDA (March 7, 2023)
February 06, 2023 05:43 ET
|
Research and Markets
Dublin, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The "cGMP Regulatory Inspections - Through the Eyes of FDA, EMA and PMDA" training has been added to ResearchAndMarkets.com's offering. GMP-compliance is...